Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01

January 3, 2023

https://www.globenewswire.com/news-release/2023/01/03/2582043/0/en/Evaxion-receives-approval-from-FDA-to-proceed-with-the-clinical-Phase-2b-study-for-EVX-01.html

COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ:EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01.

Read more at globenewswire.com

Related news for (EVAX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.